Enantioselective synthesis

Last updated

In the Sharpless dihydroxylation reaction the chirality of the product can be controlled by the "AD-mix" used. This is an example of enantioselective synthesis using asymmetric induction Key: RL = Largest substituent; RM = Medium-sized substituent; RS = Smallest substituent Sharpless Dihydroxylation Scheme.png
In the Sharpless dihydroxylation reaction the chirality of the product can be controlled by the "AD-mix" used. This is an example of enantioselective synthesis using asymmetric induction

Key: RL = Largest substituent; RM = Medium-sized substituent; RS = Smallest substituent
Two enantiomers of a generic alpha amino acid .mw-parser-output .legend{page-break-inside:avoid;break-inside:avoid-column}.mw-parser-output .legend-color{display:inline-block;min-width:1.25em;height:1.25em;line-height:1.25;margin:1px 0;text-align:center;border:1px solid black;background-color:transparent;color:black}.mw-parser-output .legend-text{} Carbon at the chiral center Carboxylic acid group R group Hydrogen Chirality with hands.svg
Two enantiomers of a generic alpha amino acid
   Carbon at the chiral center
   Carboxylic acid group
  R group
   Hydrogen

Enantioselective synthesis, also called asymmetric synthesis, [1] is a form of chemical synthesis. It is defined by IUPAC as "a chemical reaction (or reaction sequence) in which one or more new elements of chirality are formed in a substrate molecule and which produces the stereoisomeric (enantiomeric or diastereomeric) products in unequal amounts." [2]

Contents

Put more simply: it is the synthesis of a compound by a method that favors the formation of a specific enantiomer or diastereomer. Enantiomers are stereoisomers that have opposite configurations at every chiral center. Diastereomers are stereoisomers that differ at one or more chiral centers.

Enantioselective synthesis is a key process in modern chemistry and is particularly important in the field of pharmaceuticals, as the different enantiomers or diastereomers of a molecule often have different biological activity.

Overview

An energy profile of an enantioselective addition reaction. Energy diagram for enantioselective synthesis.png
An energy profile of an enantioselective addition reaction.

Many of the building blocks of biological systems such as sugars and amino acids are produced exclusively as one enantiomer. As a result, living systems possess a high degree of chemical chirality and will often react differently with the various enantiomers of a given compound. Examples of this selectivity include:

As such enantioselective synthesis is of great importance but it can also be difficult to achieve. Enantiomers possess identical enthalpies and entropies and hence should be produced in equal amounts by an undirected process – leading to a racemic mixture. Enantioselective synthesis can be achieved by using a chiral feature that favors the formation of one enantiomer over another through interactions at the transition state. This biasing is known as asymmetric induction and can involve chiral features in the substrate, reagent, catalyst, or environment [9] and works by making the activation energy required to form one enantiomer lower than that of the opposing enantiomer. [10]

Enantioselectivity is usually determined by the relative rates of an enantiodifferentiating step—the point at which one reactant can become either of two enantiomeric products. The rate constant, k, for a reaction is function of the activation energy of the reaction, sometimes called the energy barrier, and is temperature-dependent. Using the Gibbs free energy of the energy barrier, ΔG*, means that the relative rates for opposing stereochemical outcomes at a given temperature, T, is:

This temperature dependence means the rate difference, and therefore the enantioselectivity, is greater at lower temperatures. As a result, even small energy-barrier differences can lead to a noticeable effect.

ΔΔG* (kcal)k1/k2 at 273 Kk1/k2 at 298 Kk1/k2 at 323 K)
1.06
.375
.464
.78
2.040
.629
.822
.9
3.0259162109
4.01650886524
5.01050048302510

Approaches

Enantioselective catalysis

Enantioselective catalysis (known traditionally as "asymmetric catalysis") is performed using chiral catalysts, which are typically chiral coordination complexes. Catalysis is effective for a broader range of transformations than any other method of enantioselective synthesis. The chiral metal catalysts are almost invariably rendered chiral by using chiral ligands, but it is possible to generate chiral-at-metal complexes composed entirely of achiral ligands. [11] [12] [13] Most enantioselective catalysts are effective at low substrate/catalyst ratios. [14] [15] Given their high efficiencies, they are often suitable for industrial scale synthesis, even with expensive catalysts. [16] A versatile example of enantioselective synthesis is asymmetric hydrogenation, which is used to reduce a wide variety of functional groups.

Noyori Asymmetric Hydrogenation Scheme.png

The design of new catalysts is dominated by the development of new classes of ligands. Certain ligands, often referred to as "privileged ligands", are effective in a wide range of reactions; examples include BINOL, Salen, and BOX. Most catalysts are effective for only one type of asymmetric reaction. For example, Noyori asymmetric hydrogenation with BINAP/Ru requires a β-ketone, although another catalyst, BINAP/diamine-Ru, widens the scope to α,β-alkenes and aromatic chemicals.

Chiral auxiliaries

A chiral auxiliary is an organic compound which couples to the starting material to form a new compound which can then undergo diastereoselective reactions via intramolecular asymmetric induction. [17] [18] At the end of the reaction the auxiliary is removed, under conditions that will not cause racemization of the product. [19] It is typically then recovered for future use.

Auxiliary general scheme.png

Chiral auxiliaries must be used in stoichiometric amounts to be effective and require additional synthetic steps to append and remove the auxiliary. However, in some cases the only available stereoselective methodology relies on chiral auxiliaries and these reactions tend to be versatile and very well-studied, allowing the most time-efficient access to enantiomerically pure products. [18] Additionally, the products of auxiliary-directed reactions are diastereomers, which enables their facile separation by methods such as column chromatography or crystallization.

Biocatalysis

Biocatalysis makes use of biological compounds, ranging from isolated enzymes to living cells, to perform chemical transformations. [20] [21] The advantages of these reagents include very high e.e.s and reagent specificity, as well as mild operating conditions and low environmental impact. Biocatalysts are more commonly used in industry than in academic research; [22] for example in the production of statins. [23] The high reagent specificity can be a problem, however, as it often requires that a wide range of biocatalysts be screened before an effective reagent is found.

Enantioselective organocatalysis

Organocatalysis refers to a form of catalysis, where the rate of a chemical reaction is increased by an organic compound consisting of carbon, hydrogen, sulfur and other non-metal elements. [24] [25] When the organocatalyst is chiral, then enantioselective synthesis can be achieved; [26] [27] for example a number of carbon–carbon bond forming reactions become enantioselective in the presence of proline with the aldol reaction being a prime example. [28] Organocatalysis often employs natural compounds and secondary amines as chiral catalysts; [29] these are inexpensive and environmentally friendly, as no metals are involved.

Chiral pool synthesis

Chiral pool synthesis is one of the simplest and oldest approaches for enantioselective synthesis. A readily available chiral starting material is manipulated through successive reactions, often using achiral reagents, to obtain the desired target molecule. This can meet the criteria for enantioselective synthesis when a new chiral species is created, such as in an SN2 reaction.

SN2 reaction mechanism.png

Chiral pool synthesis is especially attractive for target molecules having similar chirality to a relatively inexpensive naturally occurring building-block such as a sugar or amino acid. However, the number of possible reactions the molecule can undergo is restricted and tortuous synthetic routes may be required (e.g. Oseltamivir total synthesis). This approach also requires a stoichiometric amount of the enantiopure starting material, which can be expensive if it is not naturally occurring.

Separation and analysis of enantiomers

The two enantiomers of a molecule possess many of the same physical properties (e.g. melting point, boiling point, polarity etc.) and so behave identically to each other. As a result, they will migrate with an identical Rf in thin layer chromatography and have identical retention times in HPLC and GC. Their NMR and IR spectra are identical.

This can make it very difficult to determine whether a process has produced a single enantiomer (and crucially which enantiomer it is) as well as making it hard to separate enantiomers from a reaction which has not been 100% enantioselective. Fortunately, enantiomers behave differently in the presence of other chiral materials and this can be exploited to allow their separation and analysis.

Enantiomers do not migrate identically on chiral chromatographic media, such as quartz or standard media that has been chirally modified. This forms the basis of chiral column chromatography, which can be used on a small scale to allow analysis via GC and HPLC, or on a large scale to separate chirally impure materials. However this process can require large amount of chiral packing material which can be expensive. A common alternative is to use a chiral derivatizing agent to convert the enantiomers into a diastereomers, in much the same way as chiral auxiliaries. These have different physical properties and hence can be separated and analysed using conventional methods. Special chiral derivitizing agents known as 'chiral resolution agents' are used in the NMR spectroscopy of stereoisomers, these typically involve coordination to chiral europium complexes such as Eu(fod)3 and Eu(hfc)3.

The separation and analysis of component enantiomers of a racemic drugs or pharmaceutical substances are referred to as chiral analysis. [30] or enantioselective analysis. The most frequently employed technique to carry out chiral analysis involves separation science procedures, specifically chiral chromatographic methods. [31]

The enantiomeric excess of a substance can also be determined using certain optical methods. The oldest method for doing this is to use a polarimeter to compare the level of optical rotation in the product against a 'standard' of known composition. It is also possible to perform ultraviolet-visible spectroscopy of stereoisomers by exploiting the Cotton effect.

One of the most accurate ways of determining the chirality of compound is to determine its absolute configuration by X-ray crystallography. However this is a labour-intensive process which requires that a suitable single crystal be grown.

History

Inception (1815–1905)

In 1815 the French physicist Jean-Baptiste Biot showed that certain chemicals could rotate the plane of a beam of polarised light, a property called optical activity. [32] The nature of this property remained a mystery until 1848, when Louis Pasteur proposed that it had a molecular basis originating from some form of dissymmetry, [33] [34] with the term chirality being coined by Lord Kelvin a year later. [35] The origin of chirality itself was finally described in 1874, when Jacobus Henricus van 't Hoff and Joseph Le Bel independently proposed the tetrahedral geometry of carbon. [36] [37] Structural models prior to this work had been two-dimensional, and van 't Hoff and Le Bel theorized that the arrangement of groups around this tetrahedron could dictate the optical activity of the resulting compound through what became known as the Le Bel–van 't Hoff rule.

Marckwald's brucine-catalyzed enantioselective decarboxylation of 2-ethyl-2-methylmalonic acid, resulting in a slight excess of the levorotary form of the 2-methylbutyric acid product. MarckwaldAsymmetricSynthesis.svg
Marckwald's brucine-catalyzed enantioselective decarboxylation of 2-ethyl-2-methylmalonic acid, resulting in a slight excess of the levorotary form of the 2-methylbutyric acid product.

In 1894 Hermann Emil Fischer outlined the concept of asymmetric induction; [39] in which he correctly ascribed selective the formation of D-glucose by plants to be due to the influence of optically active substances within chlorophyll. Fischer also successfully performed what would now be regarded as the first example of enantioselective synthesis, by enantioselectively elongating sugars via a process which would eventually become the Kiliani–Fischer synthesis. [40]

Brucine, an alkaloid natural product related to strychnine, used successfully as an organocatalyst by Marckwald in 1904. Brucine2.svg
Brucine, an alkaloid natural product related to strychnine, used successfully as an organocatalyst by Marckwald in 1904.

The first enantioselective chemical synthesis is most often attributed to Willy Marckwald, Universität zu Berlin, for a brucine-catalyzed enantioselective decarboxylation of 2-ethyl-2-methylmalonic acid reported in 1904. [38] [41] A slight excess of the levorotary form of the product of the reaction, 2-methylbutyric acid, was produced; as this product is also a natural product—e.g., as a side chain of lovastatin formed by its diketide synthase (LovF) during its biosynthesis [42] —this result constitutes the first recorded total synthesis with enantioselectivity, as well other firsts (as Koskinen notes, first "example of asymmetric catalysis, enantiotopic selection, and organocatalysis"). [38] This observation is also of historical significance, as at the time enantioselective synthesis could only be understood in terms of vitalism. At the time many prominent chemists such as Jöns Jacob Berzelius argued that natural and artificial compounds were fundamentally different and that chirality was simply a manifestation of the 'vital force' which could only exist in natural compounds. [43] Unlike Fischer, Marckwald had performed an enantioselective reaction upon an achiral, un-natural starting material, albeit with a chiral organocatalyst (as we now understand this chemistry). [38] [44] [45]

Early work (1905–1965)

The development of enantioselective synthesis was initially slow, largely due to the limited range of techniques available for their separation and analysis. Diastereomers possess different physical properties, allowing separation by conventional means, however at the time enantiomers could only be separated by spontaneous resolution (where enantiomers separate upon crystallisation) or kinetic resolution (where one enantiomer is selectively destroyed). The only tool for analysing enantiomers was optical activity using a polarimeter, a method which provides no structural data.

It was not until the 1950s that major progress really began. Driven in part by chemists such as R. B. Woodward and Vladimir Prelog but also by the development of new techniques. The first of these was X-ray crystallography, which was used to determine the absolute configuration of an organic compound by Johannes Bijvoet in 1951. [46] Chiral chromatography was introduced a year later by Dalgliesh, who used paper chromatography to separate chiral amino acids. [47] Although Dalgliesh was not the first to observe such separations, he correctly attributed the separation of enantiomers to differential retention by the chiral cellulose. This was expanded upon in 1960, when Klem and Reed first reported the use of chirally-modified silica gel for chiral HPLC separation. [48]

The two enantiomers of thalidomide: Left: (S)-thalidomide Right: (R)-thalidomide Thalidomide-structures.png
The two enantiomers of thalidomide:
Left: (S)-thalidomide
Right: (R)-thalidomide

Thalidomide

While it was known that the different enantiomers of a drug could have different activities, with significant early work being done by Arthur Robertson Cushny, [49] [50] this was not accounted for in early drug design and testing. However, following the thalidomide disaster the development and licensing of drugs changed dramatically.

First synthesized in 1953, thalidomide was widely prescribed for morning sickness from 1957 to 1962, but was soon found to be seriously teratogenic, [51] eventually causing birth defects in more than 10,000 babies. The disaster prompted many countries to introduce tougher rules for the testing and licensing of drugs, such as the Kefauver-Harris Amendment (US) and Directive 65/65/EEC1 (EU).

Early research into the teratogenic mechanism, using mice, suggested that one enantiomer of thalidomide was teratogenic while the other possessed all the therapeutic activity. This theory was later shown to be incorrect and has now been superseded by a body of research. [52] However it raised the importance of chirality in drug design, leading to increased research into enantioselective synthesis.

Modern age (since 1965)

The Cahn–Ingold–Prelog priority rules (often abbreviated as the CIP system) were first published in 1966; allowing enantiomers to be more easily and accurately described. [53] [54] The same year saw first successful enantiomeric separation by gas chromatography [55] an important development as the technology was in common use at the time.

Metal-catalysed enantioselective synthesis was pioneered by William S. Knowles, Ryōji Noyori and K. Barry Sharpless; for which they would receive the 2001 Nobel Prize in Chemistry. Knowles and Noyori began with the development of asymmetric hydrogenation, which they developed independently in 1968. Knowles replaced the achiral triphenylphosphine ligands in Wilkinson's catalyst with chiral phosphine ligands. This experimental catalyst was employed in an asymmetric hydrogenation with a modest 15% enantiomeric excess. Knowles was also the first to apply enantioselective metal catalysis to industrial-scale synthesis; while working for the Monsanto Company he developed an enantioselective hydrogenation step for the production of L-DOPA, utilising the DIPAMP ligand. [56] [57] [58]

Hydrogenation-Knowles1968.png AsymmetricSynthesisNoyori.png
Knowles: Asymmetric hydrogenation (1968)Noyori: Enantioselective cyclopropanation (1968)

Noyori devised a copper complex using a chiral Schiff base ligand, which he used for the metal–carbenoid cyclopropanation of styrene. [59] In common with Knowles' findings, Noyori's results for the enantiomeric excess for this first-generation ligand were disappointingly low: 6%. However continued research eventually led to the development of the Noyori asymmetric hydrogenation reaction.

The Sharpless oxyamination Sharpless Oxyamination Scheme.png
The Sharpless oxyamination

Sharpless complemented these reduction reactions by developing a range of asymmetric oxidations (Sharpless epoxidation, [60] Sharpless asymmetric dihydroxylation, [61] Sharpless oxyamination [62] ) during the 1970s and 1980s. With the asymmetric oxyamination reaction, using osmium tetroxide, being the earliest.

During the same period, methods were developed to allow the analysis of chiral compounds by NMR; either using chiral derivatizing agents, such as Mosher's acid, [63] or europium based shift reagents, of which Eu(DPM)3 was the earliest. [64]

Chiral auxiliaries were introduced by E.J. Corey in 1978 [65] and featured prominently in the work of Dieter Enders. Around the same time enantioselective organocatalysis was developed, with pioneering work including the Hajos–Parrish–Eder–Sauer–Wiechert reaction. Enzyme-catalyzed enantioselective reactions became more and more common during the 1980s, [66] particularly in industry, [67] with their applications including asymmetric ester hydrolysis with pig-liver esterase. The emerging technology of genetic engineering has allowed the tailoring of enzymes to specific processes, permitting an increased range of selective transformations. For example, in the asymmetric hydrogenation of statin precursors. [23]

See also

Related Research Articles

<span class="mw-page-title-main">BINAP</span> Chemical compound

BINAP (2,2′-bis(diphenylphosphino)-1,1′-binaphthyl) is an organophosphorus compound. This chiral diphosphine ligand is widely used in asymmetric synthesis. It consists of a pair of 2-diphenylphosphinonaphthyl groups linked at the 1 and 1′ positions. This C2-symmetric framework lacks a stereogenic atom, but has axial chirality due to restricted rotation (atropisomerism). The barrier to racemization is high due to steric hindrance, which limits rotation about the bond linking the naphthyl rings. The dihedral angle between the naphthyl groups is approximately 90°. The natural bite angle is 93°.

In chemistry, stereoselectivity is the property of a chemical reaction in which a single reactant forms an unequal mixture of stereoisomers during a non-stereospecific creation of a new stereocenter or during a non-stereospecific transformation of a pre-existing one. The selectivity arises from differences in steric and electronic effects in the mechanistic pathways leading to the different products. Stereoselectivity can vary in degree but it can never be total since the activation energy difference between the two pathways is finite: both products are at least possible and merely differ in amount. However, in favorable cases, the minor stereoisomer may not be detectable by the analytic methods used.

<span class="mw-page-title-main">William Standish Knowles</span> American chemist (1917–2012)

William Standish Knowles was an American chemist. He was born in Taunton, Massachusetts. Knowles was one of the recipients of the 2001 Nobel Prize in Chemistry. He split half the prize with Ryōji Noyori for their work in asymmetric synthesis, specifically for his work in hydrogenation reactions. The other half was awarded to K. Barry Sharpless for his work in oxidation reactions.

1,1′-Bi-2-naphthol (BINOL) is an organic compound that is often used as a ligand for transition-metal catalysed asymmetric synthesis. BINOL has axial chirality and the two enantiomers can be readily separated and are stable toward racemisation. The specific rotation of the two enantiomers is 35.5° (c = 1 in THF), with the R enantiomer being the dextrorotary one. BINOL is a precursor for another chiral ligand called BINAP. The volumetric mass density of the two enantiomers is 0.62 g cm−3.

<span class="mw-page-title-main">Chiral auxiliary</span> Stereogenic group placed on a molecule to encourage stereoselectivity in reactions

In stereochemistry, a chiral auxiliary is a stereogenic group or unit that is temporarily incorporated into an organic compound in order to control the stereochemical outcome of the synthesis. The chirality present in the auxiliary can bias the stereoselectivity of one or more subsequent reactions. The auxiliary can then be typically recovered for future use.

In chemistry, transfer hydrogenation is a chemical reaction involving the addition of hydrogen to a compound from a source other than molecular H2. It is applied in laboratory and industrial organic synthesis to saturate organic compounds and reduce ketones to alcohols, and imines to amines. It avoids the need for high-pressure molecular H2 used in conventional hydrogenation. Transfer hydrogenation usually occurs at mild temperature and pressure conditions using organic or organometallic catalysts, many of which are chiral, allowing efficient asymmetric synthesis. It uses hydrogen donor compounds such as formic acid, isopropanol or dihydroanthracene, dehydrogenating them to CO2, acetone, or anthracene respectively. Often, the donor molecules also function as solvents for the reaction. A large scale application of transfer hydrogenation is coal liquefaction using "donor solvents" such as tetralin.

In organic chemistry, kinetic resolution is a means of differentiating two enantiomers in a racemic mixture. In kinetic resolution, two enantiomers react with different reaction rates in a chemical reaction with a chiral catalyst or reagent, resulting in an enantioenriched sample of the less reactive enantiomer. As opposed to chiral resolution, kinetic resolution does not rely on different physical properties of diastereomeric products, but rather on the different chemical properties of the racemic starting materials. The enantiomeric excess (ee) of the unreacted starting material continually rises as more product is formed, reaching 100% just before full completion of the reaction. Kinetic resolution relies upon differences in reactivity between enantiomers or enantiomeric complexes.

<span class="mw-page-title-main">Organocatalysis</span> Method in organic chemistry

In organic chemistry, organocatalysis is a form of catalysis in which the rate of a chemical reaction is increased by an organic catalyst. This "organocatalyst" consists of carbon, hydrogen, sulfur and other nonmetal elements found in organic compounds. Because of their similarity in composition and description, they are often mistaken as a misnomer for enzymes due to their comparable effects on reaction rates and forms of catalysis involved.

Prolinol is a chiral amino-alcohol that is used as a chiral building block in organic synthesis. It exists as two enantiomers: the D and L forms.

Bis(oxazoline) ligands (often abbreviated BOX ligands) are a class of privileged chiral ligands containing two oxazoline rings. They are typically C2‑symmetric and exist in a wide variety of forms; with structures based around CH2 or pyridine linkers being particularly common (often generalised BOX and PyBOX respectively). The coordination complexes of bis(oxazoline) ligands are used in asymmetric catalysis. These ligands are examples of C2-symmetric ligands.

Asymmetric hydrogenation is a chemical reaction that adds two atoms of hydrogen to a target (substrate) molecule with three-dimensional spatial selectivity. Critically, this selectivity does not come from the target molecule itself, but from other reagents or catalysts present in the reaction. This allows spatial information to transfer from one molecule to the target, forming the product as a single enantiomer. The chiral information is most commonly contained in a catalyst and, in this case, the information in a single molecule of catalyst may be transferred to many substrate molecules, amplifying the amount of chiral information present. Similar processes occur in nature, where a chiral molecule like an enzyme can catalyse the introduction of a chiral centre to give a product as a single enantiomer, such as amino acids, that a cell needs to function. By imitating this process, chemists can generate many novel synthetic molecules that interact with biological systems in specific ways, leading to new pharmaceutical agents and agrochemicals. The importance of asymmetric hydrogenation in both academia and industry contributed to two of its pioneers — William Standish Knowles and Ryōji Noyori — being collectively awarded one half of the 2001 Nobel Prize in Chemistry.

Chiral Lewis acids (CLAs) are a type of Lewis acid catalyst. These acids affect the chirality of the substrate as they react with it. In such reactions, synthesis favors the formation of a specific enantiomer or diastereomer. The method is an enantioselective asymmetric synthesis reaction. Since they affect chirality, they produce optically active products from optically inactive or mixed starting materials. This type of preferential formation of one enantiomer or diastereomer over the other is formally known as asymmetric induction. In this kind of Lewis acid, the electron-accepting atom is typically a metal, such as indium, zinc, lithium, aluminium, titanium, or boron. The chiral-altering ligands employed for synthesizing these acids often have multiple Lewis basic sites that allow the formation of a ring structure involving the metal atom.

<span class="mw-page-title-main">Jacobsen's catalyst</span> Chemical compound

Jacobsen's catalyst is the common name for N,N'-bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexane­diaminomanganese(III) chloride, a coordination compound of manganese and a salen-type ligand. It is used as an asymmetric catalyst in the Jacobsen epoxidation, which is renowned for its ability to enantioselectively transform prochiral alkenes into epoxides. Before its development, catalysts for the asymmetric epoxidation of alkenes required the substrate to have a directing functional group, such as an alcohol as seen in the Sharpless epoxidation. This compound has two enantiomers, which give the appropriate epoxide product from the alkene starting material.

<span class="mw-page-title-main">DuPhos</span> Class of chemical compounds

DuPhos is a class of organophosphorus compound that are used ligands for asymmetric synthesis. The name DuPhos is derived from (1) the chemical company that sponsored the research leading to this ligand's invention, DuPont and (2) the compound is a diphosphine ligand type. Specifically it is classified as a C2-symmetric ligand, consisting of two phospholanes rings affixed to a benzene ring.

In enantioselective synthesis, a non-linear effect refers to a process in which the enantiopurity of the catalyst or chiral auxiliary does not correspond with the enantiopurity of the product produced. For example: a racemic catalyst would be expected to convert a prochiral substrate into a racemic product, but this is not always the case and a chirally enriched product can be produced instead.

Proline organocatalysis is the use of proline as an organocatalyst in organic chemistry. This theme is often considered the starting point for the area of organocatalysis, even though early discoveries went unappreciated. Modifications, such as MacMillan’s catalyst and Jorgensen's catalysts, proceed with excellent stereocontrol.

In organic chemistry, the Keck asymmetric allylation is a chemical reaction that involves the nucleophilic addition of an allyl group to an aldehyde. The catalyst is a chiral complex that contains titanium as a Lewis acid. The chirality of the catalyst induces a stereoselective addition, so the secondary alcohol of the product has a predictable absolute stereochemistry based on the choice of catalyst. This name reaction is named for Gary Keck.

In organic chemistry, carbonyl allylation describes methods for adding an allyl anion to an aldehyde or ketone to produce a homoallylic alcohol. The carbonyl allylation was first reported in 1876 by Alexander Zaitsev and employed an allylzinc reagent.

The asymmetric addition of alkynylzinc compounds to aldehydes is an example of a Nef synthesis, a chemical reaction whereby a chiral propargyl alcohol is prepared from a terminal alkyne and an aldehyde. This alkynylation reaction is enantioselective and involves an alkynylzinc reagent rather than the sodium acetylide used by John Ulric Nef in his 1899 report of the synthetic approach. Propargyl alcohols are versatile precursors for the chirally-selective synthesis of natural products and pharmaceutical agents, making this asymmetric addition reaction of alkynylzinc compounds useful. For example, Erick Carreira used this approach in a total synthesis of the marine natural product leucascandrolide A, a bioactive metabolite of the calcareous sponge Leucascandra caveolata with cytotoxic and antifungal properties isolated in 1996.

In homogeneous catalysis, C2-symmetric ligands refer to ligands that lack mirror symmetry but have C2 symmetry. Such ligands are usually bidentate and are valuable in catalysis. The C2 symmetry of ligands limits the number of possible reaction pathways and thereby increases enantioselectivity, relative to asymmetrical analogues. C2-symmetric ligands are a subset of chiral ligands. Chiral ligands, including C2-symmetric ligands, combine with metals or other groups to form chiral catalysts. These catalysts engage in enantioselective chemical synthesis, in which chirality in the catalyst yields chirality in the reaction product.

References

  1. ↑ IUPAC , Compendium of Chemical Terminology , 2nd ed. (the "Gold Book") (1997). Online corrected version: (2006–) " asymmetric synthesis ". doi : 10.1351/goldbook.A00484
  2. ↑ IUPAC , Compendium of Chemical Terminology , 2nd ed. (the "Gold Book") (1997). Online corrected version: (2006–) " stereoselective synthesis ". doi : 10.1351/goldbook.S05990
  3. ↑ Gal, Joseph (2012). "The Discovery of Stereoselectivity at Biological Receptors: Arnaldo Piutti and the Taste of the Asparagine Enantiomers-History and Analysis on the 125th Anniversary". Chirality. 24 (12): 959–976. doi:10.1002/chir.22071. PMID   23034823.
  4. ↑ Theodore J. Leitereg; Dante G. Guadagni; Jean Harris; Thomas R. Mon; Roy Teranishi (1971). "Chemical and sensory data supporting the difference between the odors of the enantiomeric carvones". J. Agric. Food Chem. 19 (4): 785–787. doi:10.1021/jf60176a035.
  5. ↑ Lepola U, Wade A, Andersen HF (May 2004). "Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder". Int Clin Psychopharmacol. 19 (3): 149–55. doi:10.1097/00004850-200405000-00005. PMID   15107657. S2CID   36768144.
  6. ↑ Hyttel, J.; Bøgesø, K. P.; Perregaard, J.; Sánchez, C. (1992). "The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer". Journal of Neural Transmission. 88 (2): 157–160. doi:10.1007/BF01244820. PMID   1632943. S2CID   20110906.
  7. ↑ JAFFE, IA; ALTMAN, K; MERRYMAN, P (October 1964). "The Antipyridoxine Effect of Penicillamine in Man". The Journal of Clinical Investigation. 43 (10): 1869–73. doi:10.1172/JCI105060. PMC   289631 . PMID   14236210.
  8. ↑ Smith, Silas W. (July 2009). "Chiral Toxicology: It's the Same Thing...Only Different". Toxicological Sciences. 110 (1): 4–30. doi: 10.1093/toxsci/kfp097 . PMID   19414517.
  9. ↑ IUPAC , Compendium of Chemical Terminology , 2nd ed. (the "Gold Book") (1997). Online corrected version: (2006–) " asymmetric induction ". doi : 10.1351/goldbook.A00483
  10. ↑ Clayden, Jonathan; Greeves, Nick; Warren, Stuart; Wothers, Peter (2001). Organic Chemistry (1st ed.). Oxford University Press. ISBN   978-0-19-850346-0.Page 1226
  11. ↑ Bauer, Eike B. (2012). "Chiral-at-metal complexes and their catalytic applications in organic synthesis". Chemical Society Reviews. 41 (8): 3153–67. doi:10.1039/C2CS15234G. PMID   22306968.
  12. ↑ Zhang, Lilu; Meggers, Eric (21 February 2017). "Steering Asymmetric Lewis Acid Catalysis Exclusively with Octahedral Metal-Centered Chirality". Accounts of Chemical Research. 50 (2): 320–330. doi:10.1021/acs.accounts.6b00586. ISSN   0001-4842. PMID   28128920.
  13. ↑ Huang, Xiaoqiang; Meggers, Eric (19 March 2019). "Asymmetric Photocatalysis with Bis-cyclometalated Rhodium Complexes". Accounts of Chemical Research. 52 (3): 833–847. doi:10.1021/acs.accounts.9b00028. ISSN   0001-4842. PMID   30840435. S2CID   73503362.
  14. ↑ N. Jacobsen, Eric; Pfaltz, Andreas; Yamamoto, Hisashi (1999). Comprehensive asymmetric catalysis 1-3. Berlin: Springer. ISBN   978-3-540-64337-1.
  15. ↑ M. Heitbaum; F. Glorius; I. Escher (2006). "Asymmetric Heterogeneous Catalysis". Angewandte Chemie International Edition . 45 (29): 4732–4762. doi:10.1002/anie.200504212. PMID   16802397.
  16. ↑ Asymmetric Catalysis on Industrial Scale, (Blaser, Schmidt), Wiley-VCH, 2004.
  17. ↑ Roos, Gregory (2002). Compendium of chiral auxiliary applications. San Diego, CA: Acad. Press. ISBN   978-0-12-595344-3.
  18. 1 2 Glorius, F.; Gnas, Y. (2006). "Chiral Auxiliaries – Principles and Recent Applications". Synthesis . 2006 (12): 1899–1930. doi:10.1055/s-2006-942399.
  19. ↑ Evans, D. A.; Helmchen, G.; Rüping, M. (2007). "Chiral Auxiliaries in Asymmetric Synthesis". In Christmann, M. (ed.). Asymmetric Synthesis – The Essentials. Wiley-VCH Verlag GmbH & Co. pp. 3–9. ISBN   978-3-527-31399-0.
  20. ↑ IUPAC , Compendium of Chemical Terminology , 2nd ed. (the "Gold Book") (1997). Online corrected version: (2006–) " Biocatalysis ". doi : 10.1351/goldbook.B00652
  21. ↑ Faber, Kurt (2011). Biotransformations in organic chemistry a textbook (6th rev. and corr. ed.). Berlin: Springer-Verlag. ISBN   978-3-642-17393-6.
  22. ↑ Schmid, A.; Dordick, J. S.; Hauer, B.; Kiener, A.; Wubbolts, M.; Witholt, B. (2001). "Industrial biocatalysis today and tomorrow". Nature. 409 (6817): 258–268. Bibcode:2001Natur.409..258S. doi:10.1038/35051736. PMID   11196655. S2CID   4340563.
  23. 1 2 Müller, Michael (7 January 2005). "Chemoenzymatic Synthesis of Building Blocks for Statin Side Chains". Angewandte Chemie International Edition. 44 (3): 362–365. doi: 10.1002/anie.200460852 . PMID   15593081.
  24. ↑ Berkessel, A.; Groeger, H. (2005). Asymmetric Organocatalysis. Weinheim: Wiley-VCH. ISBN   3-527-30517-3.
  25. ↑ Special Issue: List, Benjamin (2007). "Organocatalysis". Chem. Rev. 107 (12): 5413–5883. doi: 10.1021/cr078412e .
  26. ↑ Gröger, Albrecht Berkessel; Harald (2005). Asymmetric organocatalysis – from biomimetic concepts to applications in asymmetric synthesis (1. ed., 2. reprint. ed.). Weinheim: Wiley-VCH. ISBN   3-527-30517-3.{{cite book}}: CS1 maint: multiple names: authors list (link)
  27. ↑ Dalko, Peter I.; Moisan, Lionel (15 October 2001). "Enantioselective Organocatalysis". Angewandte Chemie International Edition. 40 (20): 3726–3748. doi:10.1002/1521-3773(20011015)40:20<3726::AID-ANIE3726>3.0.CO;2-D. PMID   11668532.
  28. ↑ Notz, Wolfgang; Tanaka, Fujie; Barbas, Carlos F. (1 August 2004). "Enamine-Based Organocatalysis with Proline and Diamines: The Development of Direct Catalytic Asymmetric Aldol, Mannich, Michael, and Diels−Alder Reactions". Accounts of Chemical Research. 37 (8): 580–591. doi:10.1021/ar0300468. PMID   15311957.
  29. ↑ Bertelsen, Søren; Jørgensen, Karl Anker (2009). "Organocatalysis—after the gold rush". Chemical Society Reviews. 38 (8): 2178–89. doi:10.1039/b903816g. PMID   19623342.
  30. ↑ Allenmark, Stig G. (1988). Chromatographic enantioseparation : methods and applications. Chichester, West Sussex, England: E. Horwood. pp. 64–66. ISBN   0-85312-988-6.
  31. ↑ Snyder, Lloyd R.; Kirkland, Joseph J.; Glajch, Joseph L. (28 February 1997). Practical HPLC Method Development. doi:10.1002/9781118592014. ISBN   978-1-118-59201-4.
  32. ↑ Lakhtakia, A., ed. (1990). Selected Papers on Natural Optical Activity (SPIE Milestone Volume 15). SPIE.
  33. ↑ Gal, Joseph (January 2011). "Louis Pasteur, language, and molecular chirality. I. Background and Dissymmetry". Chirality. 23 (1): 1–16. doi:10.1002/chir.20866. PMID   20589938.
  34. ↑ Pasteur, L. (1848). Researches on the molecular asymmetry of natural organic products, English translation of French original, published by Alembic Club Reprints (Vol. 14, pp. 1–46) in 1905, facsimile reproduction by SPIE in a 1990 book.
  35. ↑ Pedro Cintas (2007). "Tracing the Origins and Evolution of Chirality and Handedness in Chemical Language". Angewandte Chemie International Edition. 46 (22): 4016–4024. doi:10.1002/anie.200603714. PMID   17328087.
  36. ↑ Le Bel, Joseph (1874). "Sur les relations qui existent entre les formules atomiques des corps organiques et le pouvoir rotatoire de leurs dissolutions" [On the relations which exist between the atomic formulas of organic compounds and the rotatory power of their solutions]. Bull. Soc. Chim. Fr. 22: 337–347.
  37. ↑ van 't Hoff, J.H. (1874) "Sur les formules de structure dans l'espace" (On structural formulas in space), Archives Néerlandaises des Sciences Exactes et Naturelles, 9 : 445–454.
  38. 1 2 3 4 5 Koskinen, Ari M.P. (2013). Asymmetric synthesis of natural products (Second ed.). Hoboken, N.J.: Wiley. pp. 17, 28–29. ISBN   978-1-118-34733-1.
  39. ↑ Fischer, Emil (1 October 1894). "Synthesen in der Zuckergruppe II". Berichte der Deutschen Chemischen Gesellschaft. 27 (3): 3189–3232. doi:10.1002/cber.189402703109.
  40. ↑ Fischer, Emil; Hirschberger, Josef (1 January 1889). "Ueber Mannose. II". Berichte der Deutschen Chemischen Gesellschaft. 22 (1): 365–376. doi:10.1002/cber.18890220183.
  41. ↑ Marckwald, W. (1904). "Ueber asymmetrische Synthese". Berichte der Deutschen Chemischen Gesellschaft. 37: 349–354. doi:10.1002/cber.19040370165.
  42. ↑ Campbell, Chantel D.; Vederas, John C. (23 June 2010). "Biosynthesis of lovastatin and related metabolites formed by fungal iterative PKS enzymes". Biopolymers. 93 (9): 755–763. doi: 10.1002/bip.21428 . PMID   20577995.
  43. ↑ Cornish-Bawden, Athel, ed. (1997), New Beer in an Old Bottle. Eduard Buchner and the Growth of Biochemical Knowledge, Universitat de València, pp. 72–73, ISBN   978-84-370-3328-0
  44. ↑ Much of this early work was published in German, however contemporary English accounts can be found in the papers of Alexander McKenzie, with continuing analysis and commentary in modern reviews such as Koskinen (2012).
  45. ↑ McKenzie, Alexander (1 January 1904). "CXXVII.Studies in asymmetric synthesis. I. Reduction of menthyl benzoylformate. II. Action of magnesium alkyl haloids on menthyl benzoylformate". J. Chem. Soc. Trans. 85: 1249–1262. doi:10.1039/CT9048501249.
  46. ↑ Bijvoet, J. M.; Peerdeman, A. F.; van Bommel, A. J. (1951). "Determination of the Absolute Configuration of Optically Active Compounds by Means of X-Rays". Nature. 168 (4268): 271–272. Bibcode:1951Natur.168..271B. doi:10.1038/168271a0. S2CID   4264310.
  47. ↑ Dalgliesh, C. E. (1952). "756. The optical resolution of aromatic amino-acids on paper chromatograms". Journal of the Chemical Society (Resumed): 3940. doi:10.1039/JR9520003940.
  48. ↑ Klemm, L.H.; Reed, David (1960). "Optical resolution by molecular complexation chromatography". Journal of Chromatography A. 3: 364–368. doi:10.1016/S0021-9673(01)97011-6.
  49. ↑ Cushny, AR (2 November 1903). "Atropine and the hyoscyamines-a study of the action of optical isomers". The Journal of Physiology. 30 (2): 176–94. doi:10.1113/jphysiol.1903.sp000988. PMC   1540678 . PMID   16992694.
  50. ↑ Cushny, AR; Peebles, AR (13 July 1905). "The action of optical isomers: II. Hyoscines". The Journal of Physiology. 32 (5–6): 501–10. doi:10.1113/jphysiol.1905.sp001097. PMC   1465734 . PMID   16992790.
  51. ↑ McBride, W. G. (1961). "Thalidomide and Congenital Abnormalities". The Lancet. 278 (7216): 1358. doi:10.1016/S0140-6736(61)90927-8.
  52. ↑ Ito, Takumi; Ando, Hideki; Handa, Hiroshi (May 2011). "Teratogenic effects of thalidomide: molecular mechanisms". Cellular and Molecular Life Sciences. 68 (9): 1569–1579. doi:10.1007/s00018-010-0619-9. PMID   21207098. S2CID   12391084.
  53. ↑ Robert Sidney Cahn; Christopher Kelk Ingold; Vladimir Prelog (1966). "Specification of Molecular Chirality". Angewandte Chemie International Edition . 5 (4): 385–415. doi:10.1002/anie.196603851.
  54. ↑ Vladimir Prelog; Günter Helmchen (1982). "Basic Principles of the CIP-System and Proposals for a Revision". Angewandte Chemie International Edition . 21 (8): 567–583. doi:10.1002/anie.198205671.
  55. ↑ Gil-Av, Emanuel; Feibush, Binyamin; Charles-Sigler, Rosita (1966). "Separation of enantiomers by gas liquid chromatography with an optically active stationary phase". Tetrahedron Letters. 7 (10): 1009–1015. doi:10.1016/S0040-4039(00)70231-0.
  56. ↑ Vineyard, B. D.; Knowles, W. S.; Sabacky, M. J.; Bachman, G. L.; Weinkauff, D. J. (1977). "Asymmetric hydrogenation. Rhodium chiral bisphosphine catalyst". Journal of the American Chemical Society. 99 (18): 5946–5952. doi:10.1021/ja00460a018.
  57. ↑ Knowles, William S. (2002). "Asymmetric Hydrogenations (Nobel Lecture)". Angewandte Chemie International Edition. 41 (12): 1999–2007. doi:10.1002/1521-3773(20020617)41:12<1998::AID-ANIE1998>3.0.CO;2-8. PMID   19746594.
  58. ↑ Knowles, W. S. (March 1986). "Application of organometallic catalysis to the commercial production of L-DOPA". Journal of Chemical Education. 63 (3): 222. Bibcode:1986JChEd..63..222K. doi:10.1021/ed063p222.
  59. ↑ H. Nozaki; H. Takaya; S. Moriuti; R. Noyori (1968). "Homogeneous catalysis in the decomposition of diazo compounds by copper chelates: Asymmetric carbenoid reactions". Tetrahedron . 24 (9): 3655–3669. doi:10.1016/S0040-4020(01)91998-2.
  60. ↑ Katsuki, Tsutomu; Sharpless, K. Barry (1980). "The first practical method for asymmetric epoxidation". Journal of the American Chemical Society. 102 (18): 5974–5976. doi:10.1021/ja00538a077.
  61. ↑ Jacobsen, Eric N.; Marko, Istvan.; Mungall, William S.; Schroeder, Georg.; Sharpless, K. Barry. (1988). "Asymmetric dihydroxylation via ligand-accelerated catalysis". Journal of the American Chemical Society. 110 (6): 1968–1970. doi:10.1021/ja00214a053.
  62. ↑ Sharpless, K. Barry; Patrick, Donald W.; Truesdale, Larry K.; Biller, Scott A. (1975). "New reaction. Stereospecific vicinal oxyamination of olefins by alkyl imido osmium compounds". Journal of the American Chemical Society. 97 (8): 2305–2307. doi:10.1021/ja00841a071.
  63. ↑ J. A. Dale, D. L. Dull and H. S. Mosher (1969). "α-Methoxy-α-trifluoromethylphenylacetic acid, a versatile reagent for the determination of enantiomeric composition of alcohols and amines". J. Org. Chem. 34 (9): 2543–2549. doi:10.1021/jo01261a013.
  64. ↑ Hinckley, Conrad C. (1969). "Paramagnetic shifts in solutions of cholesterol and the dipyridine adduct of trisdipivalomethanatoeuropium(III). A shift reagent". Journal of the American Chemical Society. 91 (18): 5160–5162. doi:10.1021/ja01046a038. PMID   5798101.
  65. ↑ Ensley, Harry E.; Parnell, Carol A.; Corey, Elias J. (1978). "Convenient synthesis of a highly efficient and recyclable chiral director for asymmetric induction". The Journal of Organic Chemistry. 43 (8): 1610–1612. doi:10.1021/jo00402a037.
  66. ↑ Sariaslani, F.Sima; Rosazza, John P.N. (1984). "Biocatalysis in natural products chemistry". Enzyme and Microbial Technology. 6 (6): 242–253. doi:10.1016/0141-0229(84)90125-X.
  67. ↑ Wandrey, Christian; Liese, Andreas; Kihumbu, David (2000). "Industrial Biocatalysis: Past, Present, and Future". Organic Process Research & Development. 4 (4): 286–290. doi:10.1021/op990101l.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.